Management Team

Adam joined KD Pharma Group in 2018 and has since held several leadership roles, including Chief Strategy Officer and Chief Business Officer. In 2025, he was appointed Chief Commercial Officer to lead the newly established Global Commercial Department, driving growth, strengthening customer relationships, and advancing KD Pharma Group’s presence in the market.

Previously, he served as the Executive Director of the Global Organization for EPA and DHA Omega-3s, from its founding in 2007 to over 200 member companies when he left. He has spent twenty years working in the omega-3 and nutrition industries, including collaborating with other industry organizations to overturn a ban on fish oil imports in Europe; the establishment of nutritional intake recommendations and health claims in China, Europe and other countries; and co-authoring multiple scientific publications.

Prior to KD Pharma Group, he worked for Cargill, in charge of commercializing their omega-3 food ingredient business, and at Health Strategy Consulting and Health Business Partners on investment banking and strategy consulting projects, where he started the first e-mail newsletter in the nutrition industry and helped advise companies on over 150 projects and transactions
 

Mr. Thomas Strauch joined KD Pharma in July 2025, bringing with him more than 30 years of extensive international experience in finance, spanning multinational corporations, private equity-backed enterprises, and high-growth startups.

Prior to joining KD Pharma, Mr. Strauch held a series of senior finance leadership roles, including:

• Global CFO at Hilco Vision, a portfolio company of Windjammer Capital, where he led comprehensive transformation initiatives across Finance, IT, and HR. He also played a key role in the company’s financial restructuring.
• CFO of Jabra Enhance, part of GN Store Nord A/S, where he oversaw the integration of a fast-scaling direct-to-consumer tele-audiology startup, with a strong focus on profitable growth, operational efficiency, and financial discipline.
• CFO of Sivantos North America under EQT ownership, supporting its transformation into a diversified market leader through strategic investments and acquisitions.
• CFO of HearUSA, where he led the turnaround of the newly acquired U.S. retail hearing aid business for Siemens Healthcare.
  Earlier in his career, Mr. Strauch served as Director of Siemens Audit for East Asia Pacific, and held multiple finance leadership roles across the Siemens portfolio, including key positions during the spin-off of Siemens Dematic to private equity investor Triton.

Mr. Strauch holds a B.A. in Business Administration from the University of Applied Sciences in Germany, an MBA in Sales and Marketing from ICD Business School in France, and an MBA in Entrepreneurial Management from Lynn University in the United States.

Daniele Polettini joined KD Pharma in January 2014, bringing with him 15 years of experience in managing complex supply chain organisations in multinational environments. He redesigned and optimised the planning, purchasing and logistics operations of the entire KD Pharma Group, successfully supporting the company's rapid growth. From October 2024, he assumed a new responsibility within the Group as VP of Pharmaceutical Sales.

Prior to joining KD Pharma, Mr Polettini held several positions within the Fiat Group, leading large teams (>400 people) and managing global processes with significant spend (>0.5bn$) in the Supply Chain area.

Mr Polettini holds a 5 year degree in Engineering from the Polytechnic of Turin in Italy, an MBA in General Management from the Business School of the Chamber of Commerce of Valladolid in Spain and an Executive Master in Global Supply Chain from the Instituto de Empresa (IE) of Madrid in Spain.
 

Daniel Wiley joined KD Pharma in September 2021, as VP of Special Projects, where he led commercialization of KD Pharma Group emerging business units. In October 2024, he took on a new role within the Group as VP Operation Excellence. 

With over 20 years of specialty chemical and dietary supplement management expertise, he has broad operational, engineering, and commercial expertise and has built processing plants and successfully launched many new products into the market. 

Prior to joining KD Pharma, Mr. Wiley was CEO of Wiley Ingredients, where he led a team of >190 people in R&D, engineering, and manufacturing operations for a specialty chemical and nutritional ingredients manufacturer.   While at Wiley, he initiated commercial development of AlaskOmega® Omega-3 fish oil ingredients for dietary supplements and commercialized dozens of custom chemical and ingredient manufacturing projects. 

Mr. Wiley has a BS in Mechanical Engineering from Grove City College, PA and is a registered professional engineer.

Edward Gallagher joined the KD Pharma Group in January 2026 as Head of Marketing and Product Management. In this role, he leads the company's global commercial marketing strategy, product portfolio optimization, and brand positioning across the pharmaceutical and nutraceutical sectors.

Edward is a results-driven executive with over 15 years of experience leading complex international business units with P&L responsibilities up to €600M+. He has a proven track record of driving high-impact commercial transformations, optimizing global product portfolios, and accelerating high-growth innovation pipelines. 

Prior to KD Pharma, Edward held key leadership roles at GELITA AG, Clariant Pigments, Novozymes, and BASF/Cognis. 

He holds an M.Eng in Chemical Engineering from University College London and an MBA from IMD.

Scott joined KD Pharma Group in 2024, bringing 20+ years of experience in Global Supply Chain roles across multiple industries.  As a supply chain leader, Scott has created scalable and repeatable processes and implemented integrated systems and tools while leading cross functional and global organizations.

Prior to joining KD Pharma, Scott held the following positions:

Vice President – Supply Chain at Navistar Defense, where he was tasked to scale and lead production control, logistics, distribution, and supplier quality functions as well as to strengthen manufacturing capability, scale capacity, and launch production of new products.

Numerous roles of increasing responsibility within CNH Industrial, including:

Global Commodity Director – Metallic, Agriculture Segment, where he was responsible for $2B annual spend and leveraged best practices, and improved supplier relationships.

Director – China Purchasing, where during an expat assignment he scaled the purchasing function, drove cost reduction, implemented a structured sourcing process, and created a multi-year cost reduction strategy. 

Ms. Kathleen Hofmann joined the KD Pharma Group in October 2025. With over 20 years of legal leadership she brings integrity, perseverance and professionalism – navigating complex legal and strategic challenges with sound judgment and business acumen.

Prior to KD Pharma Group, Ms Hofmann worked in various roles in international industrial environments:

• Deputy General Counsel and Interim General Counsel of PROMAN, where she lead legal & compliance matters, including M&A transactions with multinational Merger Clearance, structural & legal advice to an overseas JVs and development of a Global Compliance Program.
• General Counsel of H2Energy (rebranded to morGen Energy), where she designed and implemented legal frameworks to enable scalable EU-level expansion and lead an M&A transaction.
• Senior Counsel of National Instruments AG, leading the post-merger integration of Kratzer Automation AG for legal, compliance & IP, co-developing and implementing a strategic approach to continue business operations under improved terms
• General Counsel of Kratzer Automation AG, overseeing legal & compliance, where she mitigated significant risk and led settlements negotiations with major automotive clients within a restructuring process.

• Before, Ms Hofmann held in-house counsel roles in the aviation industry in and around Munich, advising international JV’s with engine manufacturers in times of political crisis, developed agreements for green field construction in a non-EU country, lead settlement negotiations with suppliers and negotiations with Airbus. 

  Ms. Hofmann is a qualified German lawyer with a legal degree from the FAU-University in Erlangen (Germany) and holds an advanced masters in Air & Space law from the University of Leiden (Netherlands). She is also certified for the EU AI-Act and AI Governance by FernUni Schweiz. 

Mrs Federica de Gennaro joins KD Pharma Group bringing more than 20 years of experience in various HR roles. She has extensive experience creating value through human capital strategies, driving change management and transformation projects, supporting scale-up and fast growing organisations to optimal performance and growth. Instrumental in developing targeted business and marketing strategies that are budget-sensitive, customer-centric, and goal-oriented. Known for driving change through HQ relocations and organisational build-outs, M&A, and restructuring, while building trustful relations with all levels in the organisation. She possesses a strong understanding of business financials, aligning HR KPIs to optimise costs, while executing various greenfield projects and laying the foundation for HR in new business initiatives.

Prior to KD Pharma, Mrs de Gennaro held the following positions:

• HR Director EMEA of Soho Flordis International, where she re-designed the organisational structure to align with the strategic plans and improved overall financial outcomes by instilling a new work culture through designing and implementation of a change management project.
• VP HR EMEA for VF International, where she headed the Timberland integration following the acquisition, supported the fast growing businesses of The North Face and Vans by accurate talent recognition and acquisition as well as on-time execution of on-boarding and development programs. 
• HR Manager Retail Europe for Bally Shoe Factories, where she participated to the repositioning of the Brand by executing a reorganization of the stores’ portfolio 
• HR Manager for Prada Group, where she managed the whole life circle for the organizations of the Joint Ventures Companies and the acquisitions

Mrs de Gennaro has a Degree in Psychology with specialization in Work and Organizations in Italy, an Executive Master in Strategic Human Resources Management from SDA Bocconi in Italy and a Leadership Circle Certification 360 leadership assessment in UK.

Lawrence Conway joined KD Pharma, in March 2025, where he serves as the Chief of Staff, focusing on the planning and execution of key strategic initiatives. Lawrence brings over 30 years of experience driving transformation and change to large and mid-sized organizations. Through roles as a Management Consultant and Executive, he has developed broad functional expertise across Strategy, Finance, Procurement, Supply Chain, IT and Marketing and has led numerous M&A Integrations and global ERP implementations.

Prior to joining KD Pharma, Lawrence was Chief Transformation Officer at Cambrex, a private equity held CDMO where he was responsible for value creation initiatives. He also served as SVP of Procurement, IT and M&A Integration at Cantel Medical and as VP of Global Marketing and ultimately the General Manager of ConavTec’s $700m Ostomy business. 

Lawrence spent his early career as a Management Consultant working for McKinsey & Company in the UK, PwC in Switzerland, and Accenture in South Africa. 

Lawrence holds an MBA and B.Sc. (Hons) in Computer Science from the University of Cape Town.

Mr. Frank Thiel joined KD Pharma Group in 2025 as Transformation Officer, bringing more than 25 years of international C level leadership experience in general management and finance, with a strong focus on strategic and operational transformation, restructuring, and performance improvement across multinational and private equity backed businesses.

In addition, he has several years of experience in turnaround and transformation consulting, supporting companies across different industries and organizational structures.

Before joining KD Pharma Group, Mr. Thiel headed the pan-European business operations of a leading global medtech and eyewear group backed by a U.S. private equity investor. In this role, he led significant transformation initiatives and successfully executed an international build-and-buy growth strategy.

Earlier in his career, Mr. Thiel held various international C-level finance leadership positions at one of the world's leading Scandinavian industrial manufacturing groups, including EMEA Head of Finance, and led the Global Inhouse Consulting Team. In these functions, he was responsible for European operations and led large-scale transformation and performance improvement programs. Throughout his career, Mr. Thiel has led numerous complex turnaround and transformation programs focused on financial restructuring, operational efficiency, organizational development, and sustainable value creation.

He studied Business Administration in Mannheim, Germany, and completed the Executive Program in Strategic Management at IMD Lausanne, Switzerland.

Paul Lowther joined KD Pharma Group in July 2023 as Director of Global IT, bringing more than 30 years of experience across IT leadership, infrastructure, cyber security, application services, service delivery, and enterprise technology operations.

At KD Pharma, Mr Lowther is responsible for leading the transformation of IT usage across the group, with a focus on strengthening global IT governance, improving service delivery, enhancing cyber resilience, and enabling the business through secure, scalable, and fit-for-purpose technology platforms. His role supports the development of a more connected, standardised, and business-aligned IT function across multiple regions and operating environments.

Prior to joining KD Pharma, Mr Lowther held senior technology leadership roles in global pharmaceutical and healthcare organisations. At GSK, he served as Director of 3rd Party Connectivity and Head of Cyber Infrastructure, leading services that supported secure external collaboration, cyber resilience, and global technology operations in a highly regulated enterprise environment. He also held the role of Head of Application Services at Mundipharma, where he was responsible for business-critical application service delivery.

Mr Lowther is known for combining pragmatic technical expertise with strategic leadership, helping organisations improve operational effectiveness, manage technology risk, and deliver IT services that support business priorities in complex and regulated environments